For both germ cell and epithelial ovarian tumors, the first line of therapy is surgery and chemotherapy. However, there has been a lot of progress over the last few years, especially in ovarian cancer. Thus, there is a growing data base on maintenance therapy using bevacizumab and/or PARP inhibitors.